Ir para o conteúdo principal

Valneva SE (NASDAQ: VALN) — Perfil da empresa, notícias e dados financeiros

Logo de Valneva SE
VALN Valneva SE
Valneva SE  primary media
Perfil da empresa

Valneva SE

Valneva (EURONEXT:VLA), (NASDAQ:VALN) is a specialty vaccine company focused on the development, production, and commercialization of innovative vaccines for infectious diseases with significant unmet medical need. Its projects span Lyme disease, the chikungunya virus, and COVID-19, demonstrating a diversified and forward-thinking approach to global health challenges. Valneva aims to leverage its deep understanding of vaccine technology to protect people from these threats, underscoring its commitment to public health and safety. The company also prioritizes strategic partnerships and licensing agreements to enhance its vaccine portfolio and expand its reach. With a direct presence in Europe, the United States, and Asia, Valneva is dedicated to becoming a key player in the vaccine industry by delivering high-quality, life-saving vaccines across the globe.

Resumo

Public USParticipação acionária
2013Ano de fundação
621Funcionários
Saint-Herblain, FranceSede
Carregando mapa...
Presença global

Operações

Todos os locais
Republic of France

Produtos e/ou serviços de Valneva SE

  • VLA2001: COVID-19 vaccine utilizing inactivated virus technology offering an alternative to mRNA and vector-based vaccines.
  • IXIARO/JESPECT: A vaccine for Japanese encephalitis, providing crucial protection in endemic areas and for travelers.
  • Dukoral: An oral vaccine for cholera and traveler's diarrhea caused by ETEC, offering protection for travelers and high-risk populations.
  • VLA1553: Live-attenuated vaccine candidate for Chikungunya, a mosquito-borne viral disease, currently in late-stage clinical development.
  • VLA15: A vaccine candidate targeting Lyme disease, offering potential protection against the most common vector-borne illness in the Northern Hemisphere.
  • Chikungunya Antibody: A monoclonal antibody treatment for Chikungunya fever, aimed at preventing disease progression in infected individuals.

equipe executiva do Valneva SE

  • Thomas LingelbachPresident, CEO & Director
  • Peter BuhlerChief Financial Officer
  • Juan-Carlos JaramilloChief Medical Officer
  • Dipal PatelChief Commercial Officer
  • Vincent DequenneChief Operating Officer
  • Hanneke SchuitemakerChief Scientific Officer
  • Joshua DrummVice President of Investor Relations
  • Laetitia Bachelot-FontaineVP of Global Communications & European Investor Relations
  • Petra PesendorferChief People Officer
  • Katrin DubischarVP & Program Director of Chikungunya Vaccine

Principais indicadores financeiros

Resultados divulgados pela Valneva SE , em EUR.

Cap. de mercado
528,2 mi
Receita (TTM)
142,9 mi
P/L
—
LPA (diluído, TTM)
-2.1
Dividend yield
—
Margem de lucro
-110.3%
Receita e lucro anuais da Valneva SE
Fim do ano fiscalReceitaResultado operacionalLucro líquido
174,7 mi-81,6 mi-115,2 mi
169,6 mi13,3 mi-12,2 mi
153,7 mi-82,1 mi-101,4 mi
361,3 mi-113,4 mi-143,3 mi